EUCTR2016-004129-18-PL进行中（未招募）1 期
CONSERVE: rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1)Patients 18 years and above successfully treated with rVA576 (Coversin) under other Akari clinical trial protocols and wish to remain on rVA576 (Coversin)at the conclusion of that trial.
- •2)In the opinion of the treating responsible clinician patient is receiving clinical benefit from continued treatment with study drug.
- •3)Evidence of sustained total complement inhibition by CH50 assay.
- •4)Women of childbearing potential (WOCBP) must agree to use effective contraception consistently throughout the study and have a negative pregnancy test at screening.Women are considered post-menopausal and not of childbearing potential if they have had 12 months of amenorrhea and considered sterile if they have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks previously.
- •5)Males with a childbearing potential partner must agree to use effective contraception consistently OR have had a vasectomy.
- •6)Weight >50kg .
- •7)Received appropriate prophylaxis against Neisseria meningitidis infection, by both immunisation and continuous or intermittent antibiotics
- •8)Patient is willing to give voluntary written informed consent.
- •9)The patient is willing in the process of preparation and self- administration of the study drug.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 42
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 8
排除标准
- •1)Patient experienced any safety event in the previous study protocol, which puts the patient at unacceptable risk in the current protocol in the clinical judgement of the investigator and sponsor.
- •2)Patient is unwilling to complete the Quaity of Life instruments and diary card.
- •3)Active meningococcal infection (section 4.3.2 for additional information).
- •4)Any other reason for which, in the opinion of the investigator, it would not be in the interests of the patient to remain on rVA576 (Coversin).
- •5)If female, the subject is pregnant or lactating or intending to become pregnant before, during, or within 90 days after last dose; or intending to donate ova during such period.
- •6)If male, the subject intends to donate sperm during this study or for 90 days after last dose.
- •7)Failure to satisfy the Investigator of fitness to participate for any reason or any condition which, in the opinion of the investigator, could increase the subject's risk from participating in the study or confound the outcome of the study.
- •8)Use of prohibited medication (e.g. eculizumab (Soliris®), Chemotherapeutic agents, any other drug acting directly on the complement system).
- •9)The subject has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within one year prior to screening.
- •10)Participation in other clinical trials with investigational product.
研究者
相似试验
进行中（未招募）
1 期
An extension study on rVA576 (Coversin) for Patients with PNH and aHUS who received benefit from their initial studyParoxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS)MedDRA version: 21.1Level: PTClassification code 10018932Term: Haemolytic uraemic syndromeSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 21.1Level: PTClassification code 10034042Term: Paroxysmal nocturnal haemoglobinuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2016-004129-18-GBAkari Therapeutics Plc50
终止
3 期
ong Term Safety and Efficacy of Coversin in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH)Paroxysmal Nocturnal HemoglobinuriaSLCTR/2020/005Wynne Weston-Davies5
进行中（未招募）
1 期
An extension study on rVA576 (Coversin) for Patients with PNH and aHUS who received benefit from their initial studyEUCTR2016-004129-18-LTAkari Therapeutics Plc50
进行中（未招募）
1 期
An extension study on Coversin for Patients with PNH and aHUS who received benefit from their initial studyParoxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS)MedDRA version: 21.1Level: PTClassification code 10018932Term: Haemolytic uraemic syndromeSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 21.1Level: PTClassification code 10034042Term: Paroxysmal nocturnal haemoglobinuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2016-004129-18-NLAkari Therapeutics Plc50
已完成
3 期
rVA576 (Coversin) Long Term Safety and Efficacy Surveillance StudyNL-OMON48556Akari Therapeutics Plc1